Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).

A test sample and method of preparation there including a complex comprising at least binder to hGH and/or its isoforms in a blood sample obtained from a subject who is not suffering from a major cardiovascular event and/or a cardiovascular disease, wherein the complex contains more than 330 pg/ml of hGH, and/or its isoforms.

The invention relates to an ELABELA polypeptide or nucleic acid for use in the treatment, alleviation or prophylaxis of pre-eclampsia in an individual. In another aspect of the invention, there is provided a method of diagnosing or detecting the susceptibility of an individual to pre-eclampsia, wherein the method comprises detecting modulation, preferably down-regulation of expression, amount or activity of ELABELA.

Compositions and methods for treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising compound PG-20N in a pharmaceutically acceptable carrier is described. According to another embodiment, the subject disclosure features method of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment. The method may comprise administering to the subject a therapeutically effective amount of a composition comprising PG-20N. ##STR00001##

A chemical sensor for detecting a target substance in a gas sample, including a membrane; and an olfactory receptor fragment which is fixed to the membrane. The chemical sensor optionally includes a source electrode connected to one end of the membrane; and a drain electrode connected to the other end of the membrane, in which the membrane is a graphene.

This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Mllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Mllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.

The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a cancer selected in a group of cancers comprising colon cancer, liver cancer, hepatocellular carcinoma, testis cancer, thyroid cancer, gastric cancer, gastrointestinal cancer, bladder cancer, pancreatic cancer, head and neck cancer, kidney cancer, liposarcoma, pleuramesothelioma, melanoma, sarcoma, brain cancer, osteocarcinoma and leukemia.

Provided herein are methods for detecting an antigen or for detecting expression of a chimeric antigen receptor (CAR). The methods include obtaining a sample from a subject, contacting the sample with a fusion protein comprising a reporter fused to a single chain antibody specific to the antigen or fused to an extracellular domain of an antigen targeted by the CAR or fused to Protein L and assaying the activity of the reporter, wherein presence of reporter activity or increase in reporter activity relative to a reference value is indicative of presence of the antigen or presence of the expression of the chimeric antigen receptor in the sample.

The present invention relates to methods for determining the presence of pathologic amylin in a subject with diabetes or pre-diabetes. The method includes obtaining a skin sample from a subject and determining if there is pathologic amylin present in the skin sample.

A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.